Crescent Biopharma Statistics

Total Valuation

CBIO has a market cap or net worth of $796.17 million. The enterprise value is $610.04 million.

Market Cap	796.17M
Enterprise Value	610.04M

Important Dates

The next estimated earnings date is Saturday, May 23, 2026, after market close.

Earnings Date	May 23, 2026
Ex-Dividend Date	n/a

Share Statistics

CBIO has 33.23 million shares outstanding.

Current Share Class	27.57M
Shares Outstanding	33.23M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+18.68%
Owned by Insiders (%)	5.16%
Owned by Institutions (%)	44.62%
Float	14.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	75.76
Forward PS	563.84
PB Ratio	4.20
P/TBV Ratio	4.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	56.26
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.56, with a Debt / Equity ratio of 0.01.

Current Ratio	6.56
Quick Ratio	6.41
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-69.85

Financial Efficiency

Return on equity (ROE) is -160.75% and return on invested capital (ROIC) is -82.72%.

Return on Equity (ROE)	-160.75%
Return on Assets (ROA)	-69.15%
Return on Invested Capital (ROIC)	-82.72%
Return on Capital Employed (ROCE)	-74.74%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$246,455
Profits Per Employee	-$3.50M
Employee Count	44
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

In the past 12 months, CBIO has paid $2.00 million in taxes.

Income Tax	2.00M
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	15.51
200-Day Moving Average	13.25
Relative Strength Index (RSI)	66.12
Average Volume (20 Days)	267,428

Short Selling Information

The latest short interest is 2.23 million, so 6.71% of the outstanding shares have been sold short.

Short Interest	2.23M
Short Previous Month	2.24M
Short % of Shares Out	6.71%
Short % of Float	15.45%
Short Ratio (days to cover)	8.78

Income Statement

In the last 12 months, CBIO had revenue of $10.84 million and -$153.94 million in losses. Loss per share was -$12.81.

Revenue	10.84M
Gross Profit	10.84M
Operating Income	-152.63M
Pretax Income	-151.94M
Net Income	-153.94M
EBITDA	-152.55M
EBIT	-152.63M
Loss Per Share	-$12.81

Full Income Statement

Balance Sheet

The company has $213.19 million in cash and $1.64 million in debt, giving a net cash position of $211.55 million or $6.37 per share.

Cash & Cash Equivalents	213.19M
Total Debt	1.64M
Net Cash	211.55M
Net Cash Per Share	$6.37
Equity (Book Value)	203.01M
Book Value Per Share	5.99
Working Capital	200.58M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$71.53 million and capital expenditures -$919,000, giving a free cash flow of -$72.45 million.

Operating Cash Flow	-71.53M
Capital Expenditures	-919,000
Depreciation & Amortization	84,000
Net Borrowing	n/a
Free Cash Flow	-72.45M
FCF Per Share	-$2.18

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,407.52%
Pretax Margin	-1,401.16%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-18.74%
FCF Yield	-8.82%

Analyst Forecast

The average price target for CBIO is $26.67, which is 11.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$26.67
Price Target Difference	11.31%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	80.58%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CBIO has an Altman Z-Score of 2.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.1
Piotroski F-Score	1